Table 3

Associations of predictor variables with selected outcome instruments

ASDAS clinically important improvement 3 monthsASAS20 response 3 months
ORLower 95% CIUpper 95% CIORLower 95% CIUpper 95% CI
Anti-TNF vs conventional17.710.031.35.83.79.0
HLA-27+ vs HLA-27−1.30.72.21.71.12.9
Age ≤40 vs >40 years2.21.53.41.71.22.4
CRP high vs low9.35.516.02.21.43.4
CRP moderate vs low3.52.25.71.20.81.9
Berlin enthesitis score 0 vs >00.90.61.31.20.81.6
BASFI low vs high2.21.33.61.51.02.4
BASFI moderate vs high2.21.33.61.91.23.0
ASDAS major improvement 3 monthsBASDAI50 response 3 months
ORLower 95% CIUpper 95% CIORLower 95% CIUpper 95% CI
Anti-TNF vs conventional14.26.531.18.74.915.6
HLA-27+ vs HLA-27−2.41.24.72.51.44.5
Age ≤40 or >40 years1.81.22.91.91.32.8
CRP high vs low15.07.928.63.62.25.8
CRP moderate vs low4.12.27.82.31.43.7
Berlin enthesitis score 0 vs >01.61.02.51.41.02.1
BASFI low vs high1.6350.92.83.42.15.5
BASFI moderate vs high1.40.82.43.01.84.8
ASDAS inactive disease 6 monthsASAS partial remission 6 months
ORLower 95% CIUpper 95% CIORLower 95% CIUpper 95% CI
Anti-TNF vs conventional46.56.4339.616.85.254.4
HLA-27+ vs HLA-27−2.41.05.52.21.05.0
Age ≤40 or >40 years1.61.02.61.61.02.6
CRP high vs low2.31.34.22.11.23.7
CRP moderate vs low1.60.93.01.30.82.4
Berlin enthesitis score 0 vs >01.50.92.41.30.82.1
BASFI low vs high3.21.75.94.12.27.6
BASFI moderate vs high1.81.03.52.61.44.8
  • ASDAS, ankylosing spondylitis disease activity score; ASAS, assessment of spondyloarthritis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; TNF, tumour necrosis factor.